CL2024002576A1 - Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionados - Google Patents
Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionadosInfo
- Publication number
- CL2024002576A1 CL2024002576A1 CL2024002576A CL2024002576A CL2024002576A1 CL 2024002576 A1 CL2024002576 A1 CL 2024002576A1 CL 2024002576 A CL2024002576 A CL 2024002576A CL 2024002576 A CL2024002576 A CL 2024002576A CL 2024002576 A1 CL2024002576 A1 CL 2024002576A1
- Authority
- CL
- Chile
- Prior art keywords
- disorder
- macro
- medium
- substituted heterocycle
- related uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315438P | 2022-03-01 | 2022-03-01 | |
| US202363439477P | 2023-01-17 | 2023-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002576A1 true CL2024002576A1 (es) | 2025-01-10 |
Family
ID=85772026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002576A CL2024002576A1 (es) | 2022-03-01 | 2024-08-29 | Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionados |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20250236629A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4486748A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025507852A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240157067A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119110802A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023228830A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245204A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002576A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315237A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010608A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400606A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023167925A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| EP4680611A1 (en) | 2023-03-16 | 2026-01-21 | Takeda Pharmaceutical Company Limited | Macrocyclic heterocycle compounds and use thereof |
| JP2026518313A (ja) | 2023-06-01 | 2026-06-04 | ハー・ルンドベック・アクチエゼルスカベット | スピロ大環状オレキシン2受容体アゴニスト |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| US20260144795A1 (en) | 2024-11-27 | 2026-05-28 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| PE20211700A1 (es) | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
| KR20260083444A (ko) * | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| CN116635393A (zh) * | 2020-09-03 | 2023-08-22 | 欧瑞夏治疗有限公司 | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 |
-
2023
- 2023-03-01 WO PCT/US2023/014275 patent/WO2023167925A1/en not_active Ceased
- 2023-03-01 KR KR1020247032615A patent/KR20240157067A/ko active Pending
- 2023-03-01 EP EP23713207.1A patent/EP4486748A1/en active Pending
- 2023-03-01 IL IL315237A patent/IL315237A/en unknown
- 2023-03-01 TW TW112107384A patent/TW202400606A/zh unknown
- 2023-03-01 JP JP2024551975A patent/JP2025507852A/ja active Pending
- 2023-03-01 MX MX2024010608A patent/MX2024010608A/es unknown
- 2023-03-01 CA CA3245204A patent/CA3245204A1/en active Pending
- 2023-03-01 CN CN202380037293.8A patent/CN119110802A/zh active Pending
- 2023-03-01 AU AU2023228830A patent/AU2023228830A1/en active Pending
-
2024
- 2024-08-28 US US18/817,943 patent/US20250236629A1/en active Pending
- 2024-08-29 CL CL2024002576A patent/CL2024002576A1/es unknown
-
2025
- 2025-04-11 US US19/177,396 patent/US20250289828A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240157067A (ko) | 2024-10-31 |
| TW202400606A (zh) | 2024-01-01 |
| US20250289828A1 (en) | 2025-09-18 |
| JP2025507852A (ja) | 2025-03-21 |
| MX2024010608A (es) | 2024-09-23 |
| EP4486748A1 (en) | 2025-01-08 |
| AU2023228830A1 (en) | 2024-09-12 |
| CA3245204A1 (en) | 2023-09-07 |
| CN119110802A (zh) | 2024-12-10 |
| US20250236629A1 (en) | 2025-07-24 |
| WO2023167925A1 (en) | 2023-09-07 |
| IL315237A (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010608A (es) | Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados. | |
| WO2022051596A8 (en) | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | |
| ECSP21080740A (es) | Inhibidores del inflamasoma nlrp3 | |
| DOP2023000168A (es) | Compuestos antivirales que contienen nitrilo | |
| CO2022015930A2 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| CO6251367A2 (es) | Derivados de 6-amino-5-aril piridina-2il-carboxamida | |
| CO2022014160A2 (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con la modulación de p13k | |
| CO2022012476A2 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
| ECSP21080535A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| CL2022003041A1 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| CL2024003450A1 (es) | Compuestos y usos de estos | |
| UY39559A (es) | Compuestos y su uso | |
| MX2019007071A (es) | Novedosos derivados del acido fenilpropionico y usos de los mismos. | |
| AR067538A1 (es) | Inhibidortes de la 11 beta -hidroxiesteroide-deshidrogenasa | |
| NI201100137A (es) | Derivados de sulfonamida | |
| CU24327B1 (es) | Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| MX2023013987A (es) | Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer. | |
| MX2024006975A (es) | Inhibidor de cdk9 y uso del mismo. | |
| DOP2025000013A (es) | Inhibidores de inflamasoma nlrp3 | |
| AR133953A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| MX2022005843A (es) | Derivados de bencilamida como inhibidores del receptor i del factor de crecimiento transformante beta/ cinasa similar al receptor de activina 5 (alk5). | |
| AR131263A1 (es) | Compuestos de pirrolil-sulfonamida fusionados | |
| MX2023011518A (es) | Compuestos heterocíclicos novedosos y sus usos. |